Lynn Wu
Associate Professor of Operations, Information and Decisions, Wharton
Signed the letter · Academia · United States
Associate Professor of Operations, Information and Decisions at the Wharton School, University of Pennsylvania, where she teaches about the use and impact of emerging technologies. Co-author of studies on how firms use AI and robotics, including 'Artificial Intelligence, Lean Startup Method, and Product Innovations', 'Artificial Intelligence, CEO Turnover, and Exploration Orientation in Firm Innovation', and 'AI on Drugs: Can Artificial Intelligence Accelerate Drug Development?'. Signed the wemustactnow.ai open letter.
AI-written Documented facts only, from the sources below.
11 works in the co-authorship map · 1,876 citations across them
Sources
- Lynn Wu - Wharton OID Department (Associate Professor)
- Lynn Wu - LinkedIn (teaches about the use and impact of emerging technologies)
- Artificial Intelligence, Lean Startup Method, and Product Innovations
- Artificial Intelligence, CEO Turnover, and Exploration Orientation in Firm Innovation
- “Signed the wemustactnow.ai open letter” — source
In the network
5 co-authors on the map · PageRank #194 of 400 · bridge #150 of 400 · 1 step from Erik Brynjolfsson · cluster: Automation, firms and productivity.
Measured on this map only, which grows out of the letter's signatories; what these numbers mean. See Lynn Wu on the map
Documented positions
Will AI actually boost productivity and growth? unknown
No documented evidence reviewed yet.
Will AI destroy more jobs than it creates? leans disagree
Presents research finding that firms investing in robotics often hire more people overall, reducing managers rather than frontline workers, with middle-skill roles declining and high- and low-skill roles growing. The evidence concerns robotics adoption rather than AI broadly.
Evidence
Will AI widen inequality? unknown
No documented evidence reviewed yet.
Should governments act on AI now? unknown
No documented evidence reviewed yet.
How fast will the impact arrive? unknown
No documented evidence reviewed yet.
Selected work
- Artificial Intelligence, Lean Startup Method, and Product Innovations
- Artificial Intelligence, CEO Turnover, and Exploration Orientation in Firm Innovation
- AI on Drugs: Can Artificial Intelligence Accelerate Drug Development? Evidence from a Large-Scale Examination of Bio-Pharma Firms
Writes with
Bowen Lou (4), Erik Brynjolfsson (2), Lorin M. Hitt (2), Marshall Van Alstyne (1), Sinan Aral (1)
Co-authors on the map, by papers written together (5 of 5 shown).
Something wrong? Request a correction.